By otakuyassine3@gmail.com 
BioNTech SE (NASDAQ:BNTX – Get Free Report) shares traded down 2.3% during mid-day trading on Monday . The company traded as low as $116.45 and last traded at $117.63. 159,342 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 805,760 shares. The stock had previously closed at $120.38.
Wall Street Analyst Weigh In
Several equities analysts have commented on BNTX shares. HSBC raised their target price on shares of BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research note on Monday, October 7th. BMO Capital Markets reissued an “outperform” rating on shares of BioNTech in a report on Monday, December 2nd. TD Cowen cut their target price on BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research report on Tuesday, November 5th. Berenberg Bank began coverage on BioNTech in a research report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price target on the stock. Finally, Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and upped their price objective for the company from $110.00 to $125.00 in a report on Tuesday, November 19th. Four analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $140.76.
Read Our Latest Report on BioNTech
BioNTech Trading Down 4.9 %
The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The stock has a market cap of $26.53 billion, a price-to-earnings ratio of -53.15 and a beta of 0.22. The company has a fifty day simple moving average of $113.66 and a 200-day simple moving average of $100.66.
BioNTech (NASDAQ:BNTX – Get Free Report) last released its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm’s revenue was up 38.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.73 earnings per share. On average, research analysts forecast that BioNTech SE will post -3.72 earnings per share for the current fiscal year.
Institutional Trading of BioNTech
A number of hedge funds have recently modified their holdings of the business. Slow Capital Inc. raised its position in BioNTech by 12.0% during the second quarter. Slow Capital Inc. now owns 51,080 shares of the company’s stock valued at $4,105,000 after buying an additional 5,467 shares during the period. Van ECK Associates Corp lifted its position in shares of BioNTech by 1.9% in the second quarter. Van ECK Associates Corp now owns 119,901 shares of the company’s stock worth $9,635,000 after purchasing an additional 2,192 shares in the last quarter. Investmentaktiengesellschaft Fuer Langfristige Investoren TGV boosted its holdings in shares of BioNTech by 41.4% during the second quarter. Investmentaktiengesellschaft Fuer Langfristige Investoren TGV now owns 20,500 shares of the company’s stock worth $1,647,000 after purchasing an additional 6,000 shares during the period. TD Asset Management Inc grew its position in BioNTech by 6.1% during the second quarter. TD Asset Management Inc now owns 7,590 shares of the company’s stock valued at $612,000 after purchasing an additional 435 shares in the last quarter. Finally, Candriam S.C.A. increased its stake in BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after buying an additional 418,695 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.
BioNTech Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Featured Articles
Receive News & Ratings for BioNTech Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioNTech and related companies with MarketBeat.com’s FREE daily email newsletter.